Thomas J. Herzog, MD

PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse

April 25th 2024

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations

August 2nd 2023

Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.

Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

August 2nd 2023

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

Commercially Available 
HRD Tests for Ovarian Cancer

July 27th 2023

The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.

Other Causes of HRD: Chromosomal LOH, LST, and TAI

July 27th 2023

Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.

Defining HRD and its Role in Ovarian Cancer

July 20th 2023

Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).

Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann

July 20th 2023

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.

Systemic Management of Ovarian Cancer: Closing Thoughts

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

May 27th 2020

Ovarian Cancer: What is the Role of HRD Testing?

May 27th 2020

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

May 27th 2020